Cynapsus Therapeutics To Present Three Posters at 68th American Academy Of Neurology Annual Meeting

Cynapsus Therapeutics Inc CYNA disclosed that it would present three clinical posters at the 68th Americal Academy of Neurology Annual Meeting to be held on April 17 in Vancouver in Canada. According to the company, the first of the three presentations exhibits efficacy data from its CTH-105 Phase two trial using a sublingual thin film of apomorphine, APL-130277, to treat adult patients of OFF episodes with PD.

Cynapsus Therapeutics said that the results exhibited patients' mean time to full ON of 24 minutes, as well as, mean duration of ON of fifty minutes. Apart from that, there was a significant statistical and clinical enhancement in motor function, at all time-points, as measured by Movement Disorder Society Unified-Parkinson's Disease Rating Scale.

The company stated that the second poster presentation was in respect of the safety data from the same trial with the safety conclusions indicating that APL-130277 was generally well-tolerated. Similarly, the third poster focused on the effects of sublingual apomorphine by disease severity on the acute management of OFF episodes in PD. The company said that the results showed that APL-130277 rapidly converts PD patients of various disease severities from OFF to the full ON state.

Cynapsus Therapeutics Chief Medical Officer, Albert Agro, said "The clinical data for APL-130277 in treating OFF episodes in Parkinson's disease continue to be encouraging. The efficacy and safety data across a range of patients provide important insights on how our product candidate could be used to improve patient care."

The CMO said, "Solid results from our Phase 2 study provide us confidence and optimism as we look forward to reporting clinical data from our Pivotal Phase 3 efficacy trial over the next several months. We anticipate that these data will be used to file our new drug application ("NDA") near the end of 2016 or in early 2017."

On Thursday, the stock closed with a gain of 4.17 percent.